Roberts Nicholas L S, Fadhil Salama, Willkens Megan, Ruselu Grace, Desderius Bernard, Kanenda Said, Rudovick Ladius, Kavishe Bazil B, Koenig Serena P, Tummalapalli Sri Lekha, Lee Myung Hee, Peck Robert N
Center for Global Health, Weill Cornell Medicine, New York, NY.
Department of Internal Medicine, Bugando Medical Centre and Weill Bugando School of Medicine, Mwanza, Tanzania.
Kidney Med. 2024 Nov 15;7(1):100937. doi: 10.1016/j.xkme.2024.100937. eCollection 2025 Jan.
RATIONALE & OBJECTIVE: Longitudinal research on chronic kidney disease (CKD) in sub-Saharan Africa is sparse, especially among people living with HIV (PLWH). We evaluated the incidence of CKD among PLWH compared with HIV-uninfected controls in Tanzania.
Prospective cohort study.
SETTING & PARTICIPANTS: A total of 495 newly diagnosed PLWH who initiated antiretroviral therapy (ART) and 505 HIV-uninfected adults enrolled from public HIV clinics and followed from 2016-2021. The control group was recruited from HIV treatment partners from the same HIV clinics.
Untreated HIV (at baseline), ART, sociodemographic information, health behaviors, hypertension, and diabetes.
Incident CKD, defined as a follow-up estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m with ≥25% reduction from baseline; annual eGFR change; incident albuminuria; 3-year all-cause mortality.
Multivariable Poisson and linear regression determined the association between HIV and other factors with a baseline prevalent reduced eGFR and albuminuria, incident CKD and albuminuria, and annual eGFR change. Cox hazard regression assessed the association between baseline CKD and mortality.
Median age was 35 years and 67.5% were women. There were 101 incident CKD cases, 71 among PLWH and 30 among HIV-uninfected participants, equivalent to a CKD incidence of 57.9 per 1,000 person-years (95% CI, 44.4-71.4) and 26.2 per 1,000 person-years (95% CI, 16.8-35.5), respectively. PLWH had a more rapid eGFR decline (-6.65 vs -2.61 mL/min/1.73 m per year). Female sex and older age were positively associated with incident CKD. Albuminuria incidence did not differ by HIV status. PLWH with albuminuria at baseline had higher mortality (HR, 2.13; 95% CI, 1.08-4.21).
As an observational cohort study, there was no comparison group of HIV-positive participants on a nontenofovir disoproxil fumarate-based ART regimen.
PLWH receiving tenofovir disoproxil fumarate-based ART had a very high incidence of CKD and rapid eGFR decline. Conversely, albuminuria stabilized with ART use. Expanding access to less-nephrotoxic ART, such as tenofovir alafenamide, is urgently needed throughout sub-Saharan Africa.
撒哈拉以南非洲地区关于慢性肾脏病(CKD)的纵向研究较少,尤其是在艾滋病毒感染者(PLWH)中。我们评估了坦桑尼亚PLWH与未感染艾滋病毒的对照组相比CKD的发病率。
前瞻性队列研究。
共有495名新诊断的开始抗逆转录病毒治疗(ART)的PLWH和505名未感染艾滋病毒的成年人,他们来自公共艾滋病毒诊所,并于2016年至2021年进行随访。对照组从同一艾滋病毒诊所的艾滋病毒治疗伙伴中招募。
未治疗的艾滋病毒(基线时)、ART、社会人口统计学信息、健康行为、高血压和糖尿病。
新发CKD,定义为随访估计肾小球滤过率(eGFR)<60 mL/min/1.73 m²且较基线降低≥25%;年度eGFR变化;新发白蛋白尿;3年全因死亡率。
多变量泊松回归和线性回归确定艾滋病毒及其他因素与基线时eGFR降低和白蛋白尿、新发CKD和白蛋白尿以及年度eGFR变化之间的关联。Cox风险回归评估基线CKD与死亡率之间的关联。
中位年龄为35岁,67.5%为女性。共有101例新发CKD病例,PLWH中有71例,未感染艾滋病毒参与者中有30例,CKD发病率分别为每1000人年57.9例(95%CI,44.4 - 71.4)和每1000人年26.2例(95%CI,16.8 - 35.5)。PLWH的eGFR下降更快(每年-6.65 vs -2.61 mL/min/1.73 m²)。女性和年龄较大与新发CKD呈正相关。白蛋白尿发病率在艾滋病毒状态方面无差异。基线时有白蛋白尿的PLWH死亡率更高(HR,2.13;95%CI,1.08 - 4.21)。
作为一项观察性队列研究,没有基于非富马酸替诺福韦二吡呋酯的ART方案的艾滋病毒阳性参与者的比较组。
接受基于富马酸替诺福韦二吡呋酯的ART的PLWH中CKD发病率非常高且eGFR下降迅速。相反,使用ART后白蛋白尿稳定。在整个撒哈拉以南非洲地区,迫切需要扩大使用肾毒性较小的ART,如替诺福韦艾拉酚胺。